Search

Displaying results 1351 - 1360 of 4207 in total
  1. Drug

    Thioredoxin

    go.drugbank.com/drugs/DB11298
    Approved

    Allergens containing disulfide bonds are inactivated when reduced by thioredoxin. … It is a 12-kD oxidoreductase enzyme encoded by TXN and TXN2 genes that contains a dithiol-disulfide active site.

  2. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    It is an investigational drug under regulatory review by FDA. … Vernakalant was developed by Cardiome Pharma as as an antiarrhythmic drug intended for rapid conversion of atrial fibrillation to sinus rhythm.

  3. Drug

    Padeliporfin

    go.drugbank.com/drugs/DB15575
    ApprovedInvestigational

    [A244699] Padeliporfin was first approved by the European Commission on November 10, 2017, for the treatment of low-risk prostate cancer in adults meeting certain clinical criteria.[L39799]

  4. Drug

    Parathyroid hormone

    go.drugbank.com/drugs/DB05829
    ApprovedInvestigational

    Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA). … Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed.

  5. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    by a reduced number of mature neutrophils and lymphocytes. … [L50647] WHIM syndrome is caused by mutations in the _CXCR4_ gene, which leads to overactivation of CXCR4 signalling pathways.[A263652] Mavorixafor prevents the activation of CXCR4.

  6. Drug

    Evolocumab

    go.drugbank.com/drugs/DB09303
    ApprovedInvestigational

    Evolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. … It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.

  7. Drug

    Mannitol

    go.drugbank.com/drugs/DB00742
    ApprovedInvestigational

    this indication under the name BRONCHITOL® by Chiesi USA Inc. … On October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for

  8. Drug

    Ibrutinib

    go.drugbank.com/drugs/DB09053
    ApprovedInvestigational

    [L45894] Ibrutinib was approved by the EMA in October 2014 [L45884] and by Health Canada in November 2014. … [A32299] Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval;[L12228] however, in

  9. Drug

    Chenodeoxycholic acid

    go.drugbank.com/drugs/DB06777
    ApprovedInvestigational

    It works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.

  10. Drug

    Acetyl sulfisoxazole

    go.drugbank.com/drugs/DB14033
    ApprovedVet approved

    It is often combined with erythromycin to treat acute otitis media caused by the bacteria, haemophilus influenzae [L2790].